S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone

This study has been withdrawn prior to enrollment.
(withdrawn support for study)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00301886
First received: March 9, 2006
Last updated: November 11, 2013
Last verified: November 2013

March 9, 2006
November 11, 2013
May 2006
May 2006   (final data collection date for primary outcome measure)
Skeletal-related events (SRE)
Not Provided
Complete list of historical versions of study NCT00301886 on ClinicalTrials.gov Archive Site
  • Change in patient's rating of worst pain as measured by the Brief Pain Inventory
  • Survival and time to first clinically apparent SRE
  • Tolerability and toxicity as measured by NCI CTCAE v3.0
  • Changes in performance status
Not Provided
Not Provided
Not Provided
 
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer

RATIONALE: Zoledronate and ibandronate may prevent or help relieve bone pain and other symptoms caused by bone metastases. It is not yet known whether zoledronate is more effective than ibandronate in preventing bone problems caused by bone metastases due to breast cancer.

PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to ibandronate in preventing bone problems in women with stage IV breast cancer that has spread to the bone.

OBJECTIVES:

Primary

  • Compare the efficacy of zoledronate vs ibandronate, in terms of preventing the occurrence of skeletal-related events (SRE) (e.g., fracture, spinal cord compression, radiotherapy or surgery for bone symptoms or events, or hypercalcemia ≥ grade 3), in women with stage IV breast cancer and bone metastases.

Secondary

  • Compare the change in patient-reported measures of pain and use of analgesics in patients treated with these drugs.
  • Compare the time to first clinically apparent SRE in patients treated with these drugs.
  • Compare the toxicity of these drugs.
  • Compare the changes in performance status and overall survival of patients treated with these drugs.

OUTLINE: This is a multicenter, randomized study. Patients are stratified according to hormone receptor status (estrogen receptor [ER] and progesterone receptor [PR] negative vs ER and/or PR positive) and current evidence of fracture (vertebral or nonvertebral) or spinal compression (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral ibandronate once daily on days 1-28.
  • Arm II: Patients receive zoledronate IV over 15 minutes on day 1. In both arms, treatment repeats every 28 days for up to 18 courses in the absence of unacceptable toxicity.

Quality of life and pain are assessed at baseline, every 3 courses during study treatment, and at the end of study treatment.

After completion of study treatment, patients are followed periodically for up to 3 years.

PROJECTED ACCRUAL: A total of 488 patients will be accrued for this study.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Breast Cancer
  • Hypercalcemia of Malignancy
  • Metastatic Cancer
  • Pain
  • Drug: ibandronate
    Other Name: ibandronate sodium
  • Drug: zoledronate
    Other Name: zoledronic acid
  • Procedure: quality-of-life assessment
  • Experimental: zoledronate
    zoledronate
    Interventions:
    • Drug: zoledronate
    • Procedure: quality-of-life assessment
  • Experimental: ibandronate
    ibandronate
    Interventions:
    • Drug: ibandronate
    • Procedure: quality-of-life assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 2006
May 2006   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed stage IV breast cancer at primary diagnosis or at recurrence

    • Any T, any N, M1
  • At least 1 dominant osteolytic or osteoblastic or mixed metastatic lesion outside any prior radiation field

    • Lesion measures ≥ 1.0 cm by x-ray, CT scan, and/or MRI
  • Controlled asymptomatic brain metastases allowed
  • Controlled bone pain, defined as a physician/health care provider rating of ≤ grade 2 pain-SELECT (Bone) on the NCI CTC for Adverse Events Version 3.0 rating scale, required
  • Current evidence of vertebral or nonvertebral fractures or spinal compression due to cancer, as determined by the treating physician, allowed
  • No Paget's disease of the bone
  • Estrogen receptor (ER) or progesterone receptor (PR) status known

PATIENT CHARACTERISTICS:

  • Female patient
  • Menopausal status not specified
  • Zubrod performance status 0-2
  • Creatinine normal
  • Creatinine clearance ≥ 60 mL/min
  • Serum calcium < 12 mg/dL
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Must be able to receive IV medication and oral medication (i.e., must have physical integrity of the upper gastrointestinal tract)
  • No malabsorption syndrome
  • No primary hyperparathyroidism
  • No known history of aspirin-sensitive asthma
  • No other prior malignancy except for the following:

    • Adequately treated basal cell or squamous cell skin cancer
    • In situ cervical cancer
    • Adequately treated stage I or II cancer currently in complete remission
    • Any other cancer for which the patient has been disease-free for at least 5 years
  • No uncontrolled medical illness or infection, including, but not limited to, the following:

    • Unstable angina
    • Recent myocardial infarction
    • Life-threatening cardiac arrhythmia

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior bisphosphonates for metastatic bone disease
  • More than 28 days since prior aminoglycoside antibiotics
  • At least 28 days since prior oral bisphosphonates for osteoporosis
  • More than 6 months since prior bisphosphonates used for adjuvant therapy
  • Concurrent treatment, including chemotherapy, hormonal therapy, and/or biologic therapy for metastatic breast cancer allowed
  • No concurrent participation in another clinical treatment trial for this cancer unless the patient is no longer receiving the intervention and is in the follow-up phase of the other clinical trial
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00301886
CDR0000463758, S0308, U10CA037429
Yes
Southwest Oncology Group
Southwest Oncology Group
National Cancer Institute (NCI)
Study Chair: Saul E. Rivkin, MD Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Study Chair: Kathy S. Albain, MD Loyola University
Study Chair: Dawn Hershman, MD Herbert Irving Comprehensive Cancer Center
Southwest Oncology Group
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP